Tracey Walker

An Avalere analysis finds that this factor plays an important role in the era of value-based payment. Find out what it is.

Here’s what’s shaking up the drug launch pricing space. Experts weigh in.

Managed Healthcare Executive asked experts to identify Trump’s top priorities within the plan, and how those priorities could affect managed care.

Managed Healthcare Executive asked experts to weigh in on Trump’s new blueprint to tackle drug market challenges. Here’s what they said.

Managed Healthcare Executive asked healthcare executives about their interview techniques, how they approach job interviews, and the one doozy of a question that they like to ask job candidates. Here’s what they said.

A new HealthMine survey of Medicare beneficiaries has surprising results about this population’s digital health literacy.

Payers are becoming more receptive to a different approach for paying for addiction treatment and recovery services, as evidenced by the formation of a new healthcare alliance that aims to redesign the structure and payment of these services.

If all consumers had a high understanding of how to navigate the healthcare system, health insurers could save billions of dollars a year. Here’s what you should do.

Making medications more affordable to patients is linked to better adherence, with no added costs, according to a new study.

NORC at the University of Chicago set out to understand more Americans’ experiences with surprise billing. You won’t believe what they found.

Surprising findings from the largest study to date investigating the genetics of osteoporosis and fracture risk.

New Accenture research reveals how artificial intelligence can net health insurers big bucks.

A report by eHealth, Inc., has surprising findings about seniors transitioning from unsubsidized ACA plans into Medicare

Promising new technology/biotechnology is on the horizon for migraine sufferers, according to a headache expert from Cleveland Clinic.

A new forecast reveals an important focus point for healthcare execs in the quest to manage pharma costs.

Combat stress, PTSD, depression, anxiety, and substance use disorder are genuine, serious and treatable medical conditions. Here’s how one operator is tackling all of them.

A HealthMine survey has interesting results about Medicare Advantage members’ knowledge about virtual care. Here’s six ways to reach them.

Medical malpractice companies partner to provide a detailed analysis of breast cancer medical malpractice claims. The findings may surprise you.

A new study may offer healthcare organizations a new way to close gaps in care while simultaneously engaging the patient as a partner in care.

New research from Prophet shares five key shifts healthcare organizations can make in the move toward consumer-centricity.

A new survey has shocking results about consumer knowledge of health insurance.

Managed Healthcare Executive asked key opinion leaders their thoughts on the drug rebate controversy. Here’s what they said.

FDA’s new guidance provides a roadmap for health executives on incorporating EHRs into clinical trials.

A new survey from HealthMine reveals shocking findings about connecting with Medicare Advantage members who have chronic conditions.

A survey from Imprivata has surprising findings about the magnitude of the patient matching problem.

Are recent pharma price drops just a response to political pressure or will the momentum last? Managed Healthcare Executive asked industry experts, and here’s what they said.

Annual Health Care CEO Survey sheds light on the areas of extreme interest to hospital and health system executives. The results may surprise you.

Amazon captured the industry’s attention once again when it announced it is acquiring online pharmacy PillPack for a reported $1 billion. Here’s how experts say it will affect managed care.

A Quest Diagnostics survey has surprising results about perceptions of physicians and health plan executives on progress toward value-based healthcare.

Drug costs are increasing, but so is patient cost sharing. That’s raising serious problems for some patients. Here are seven of the most out-of-reach drugs due to high costs, according to industry watchers.